UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1382) 1382
life sciences & biomedicine (1246) 1246
humans (1208) 1208
proto-oncogene proteins c-abl - metabolism (961) 961
animals (839) 839
mice (564) 564
biochemistry & molecular biology (552) 552
proto-oncogene proteins c-abl - genetics (535) 535
cell biology (467) 467
phosphorylation (455) 455
oncology (340) 340
proto-oncogene proteins c-abl - antagonists & inhibitors (323) 323
c-abl (315) 315
imatinib mesylate (296) 296
signal transduction (264) 264
hemic and lymphatic diseases (248) 248
cell line (236) 236
benzamides (234) 234
pyrimidines - pharmacology (234) 234
female (222) 222
molecular sequence data (220) 220
male (219) 219
protein binding (214) 214
proto-oncogene proteins c-abl - chemistry (214) 214
research (203) 203
tyrosine (202) 202
amino acid sequence (199) 199
apoptosis (197) 197
proteins (188) 188
cell line, tumor (184) 184
piperazines - pharmacology (184) 184
protein kinase inhibitors - pharmacology (178) 178
protein-tyrosine kinases - metabolism (168) 168
cells, cultured (167) 167
kinases (166) 166
proto-oncogene proteins c-abl - physiology (158) 158
hematology (154) 154
mutation (148) 148
binding sites (145) 145
cancer (127) 127
enzyme activation (127) 127
antineoplastic agents - pharmacology (125) 125
genetics & heredity (125) 125
neoplasms (125) 125
leukemia, myelogenous, chronic, bcr-abl positive - genetics (123) 123
analysis (121) 121
tyrosine - metabolism (120) 120
leukemia (119) 119
science & technology - other topics (119) 119
transfection (119) 119
models, molecular (118) 118
multidisciplinary sciences (118) 118
research article (117) 117
dna damage (116) 116
src homology domains (110) 110
proto-oncogene proteins - genetics (107) 107
physiological aspects (106) 106
tumor cells, cultured (105) 105
proto-oncogene proteins c-abl (103) 103
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (99) 99
protein structure, tertiary (99) 99
adult (98) 98
gene expression (97) 97
genetic aspects (97) 97
apoptosis - drug effects (94) 94
fusion proteins, bcr-abl - genetics (94) 94
base sequence (93) 93
dna-binding proteins - metabolism (93) 93
imatinib (93) 93
biophysics (89) 89
protein-tyrosine kinases - genetics (89) 89
mice, knockout (87) 87
nuclear proteins - metabolism (86) 86
pyrimidines - therapeutic use (86) 86
abl (85) 85
rats (85) 85
abridged index medicus (84) 84
middle aged (84) 84
genes, abl (82) 82
protein conformation (81) 81
protein-tyrosine kinases - antagonists & inhibitors (80) 80
signal transduction - drug effects (80) 80
chronic myeloid leukemia (78) 78
phosphorylation - drug effects (77) 77
phosphotransferases (75) 75
biology (74) 74
pharmacology & pharmacy (73) 73
blotting, western (72) 72
structure-activity relationship (72) 72
piperazines - therapeutic use (71) 71
leukemia, myelogenous, chronic, bcr-abl positive - pathology (70) 70
cell cycle (69) 69
cell proliferation (69) 69
proto-oncogene proteins - metabolism (68) 68
chemistry (67) 67
protein kinases (66) 66
biochemistry (65) 65
gene expression regulation (65) 65
protein kinase inhibitors - chemistry (65) 65
signal transduction - physiology (64) 64
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1723) 1723
Chinese (50) 50
Japanese (15) 15
German (3) 3
French (2) 2
Russian (2) 2
Spanish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cell (Cambridge), ISSN 0092-8674, 2003, Volume 112, Issue 6, pp. 859 - 871
Journal Article
Cancer cell, ISSN 1535-6108, 11/2009, Volume 16, Issue 5, pp. 401 - 412
Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain... 
CHEMBIO | HUMDISEASE | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Pyridazines - pharmacology | Protein Kinase Inhibitors - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Antineoplastic Agents - pharmacology | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Cell Growth Processes - drug effects | Proto-Oncogene Proteins c-abl - chemistry | Models, Molecular | Imidazoles - pharmacology | Antineoplastic Agents - chemistry | Mice, SCID | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Animals | Signal Transduction - drug effects | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Proto-Oncogene Proteins c-abl - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Fusion Proteins, bcr-abl - metabolism | Chronic myeloid leukemia | BCR protein | Imatinib | Mutagenesis | Abl protein | Mutation | Fusion protein | Tumors | Index Medicus | imatinib resistance | dasatinib | nilotinib | compound mutation
Journal Article
Cell (Cambridge), ISSN 0092-8674, 03/2003, Volume 112, Issue 6, pp. 845 - 857
Journal Article
Nature (London), ISSN 1476-4687, 02/2015, Volume 519, Issue 7541, pp. 102 - 105
The BCR-ABL1 fusion gene is a driver oncogene in chronic myeloid leukaemia and 30-50% of cases of adult acute lymphoblastic leukaemia(1). Introduction of ABL1... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Molecular Conformation | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Protein Kinase Inhibitors - chemistry | Angiogenesis Inhibitors - therapeutic use | Imidazoles - therapeutic use | Phosphorylation - drug effects | Fusion Proteins, bcr-abl - chemistry | Cell Line | Proto-Oncogene Proteins c-abl - genetics | Indazoles - chemistry | Crystallization | Proto-Oncogene Proteins c-abl - chemistry | Angiogenesis Inhibitors - pharmacology | Models, Molecular | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Imidazoles - pharmacology | Drug Repositioning | Indazoles - pharmacology | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Vascular Endothelial Growth Factor Receptor-2 - chemistry | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Protein Binding | Proto-Oncogene Proteins c-abl - metabolism | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Kidney Neoplasms - drug therapy | Fusion Proteins, bcr-abl - metabolism | Indazoles - therapeutic use | Angiogenesis Inhibitors - chemistry | Drug Screening Assays, Antitumor | Axitinib | Genetic aspects | Research | Gene mutations | Drug resistance | Analysis | Phosphorylation | Inhibitor drugs | Leukemia | Bone marrow | Mutation | Kinases | Drug dosages | Patients | Index Medicus | Medicin och hälsovetenskap
Journal Article
Journal Article